Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118819 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
A Phase 1 study, sponsored by BioMed Valley Discoveries.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01118819 is a Phase 1 study that was terminated before completion, run by BioMed Valley Discoveries. The registered enrollment target is 5 participants.
The verdict
NCT01118819, a Phase 1 study, was terminated before completion, sponsored by BioMed Valley Discoveries.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This protocol will examine the safety of intravenous administration of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C. novyi-NT administered intravenously in patients with treatment-refractory solid tumor malignancies.
Interventions
- BIOLOGICAL Clostridium novyi-NT spores
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01118819
The ClinicalTrials.gov registry entry for NCT01118819 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMed Valley Discoveries, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clostridium novyi-NT spores is the first listed.
NCT01118819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01118819 about?
NCT01118819 is a clinical study titled "Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies". This protocol will examine the safety of intravenous administration of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C. novyi-NT administered intravenously in patients with treatment-refracto...
What is the current status of trial NCT01118819?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2011-04. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01118819?
The interventions under investigation include: Clostridium novyi-NT spores (BIOLOGICAL).
Who is sponsoring clinical trial NCT01118819?
This trial is sponsored by BioMed Valley Discoveries, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.